Family Med Medical News about Exenatide Sitagliptin

Your Unread Messages

See All

Hello, Mary O'connor
Manage E-mail | Logout

Most Viewed Abstracts

1. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

2. Omega-3 fatty acids for bipolar disorder

3. Is folic acid good for everyone

4. ACS Releases Guidelines for HPV Vaccination

5. Vitamin D - A review Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

FDA Approves Revisions to Prescribing Information for Diabetes Medications
American Family Physician, 11/06/09

The FDA is revising the prescribing information for the injectable diabetes medication exenatide and the oral diabetes drug sitagliptin phosphate following reports of renal problems associated with exenatide use, as well as reports linking sitagliptin use with pancreatitis.

<< Previous
Spider bites - Assessment and management

Next >>
Management of mammalian bites

Sitagliptin 100mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement
Current Medical Research and Opinion, 10/08/09 Relevance Score: 45%

Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study
Diabetes, Obesity and Metabolism, 11/12/09 Relevance Score: 44%

The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics
Diabetes, Obesity and Metabolism, 11/12/09 Relevance Score: 44%

Sitagliptin treatment of patients with type 2 diabetes does not affect CD4+ T-cell activation
Journal of Diabetes and its Complications, 10/29/09 Relevance Score: 43%

Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting
Diabetes, Obesity and Metabolism, 10/06/09 Relevance Score: 43%